Document is current
Any future updates will be listed below
-
Authors
Iwata, Satoshi
Pollard, Andrew J.
Tada, Yukio
Omoto, Shinya
Shibata, Risa Y.
Igarashi, Kenji
Hasegawa, Takahiro
Ariyasu, Mari https://orcid.org/0000-0002-5109-9448
Sonoyama, Takuhiro
- License Information
-
More Information
Article History
Received: 1 August 2023
Accepted: 17 March 2024
First Online: 29 April 2024
Competing interests
: SI received payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing, and educational events from Astellas Pharma Inc., Gilead Sciences, Inc., Japan Vaccine Co., Ltd., Meiji Seika Pharma Co., Ltd., Pfizer Japan Inc., and Taisho Toyama Pharmaceutical Co. Ltd., in addition to consulting fees from Shionogi & Co., Ltd. for advisory board participation. AJP is chair of the UK Department of Health and Social Care’s (DHSC) Joint Committee on Vaccination and Immunisation (JCVI) but does not take part in the JCVI COVID-19 committee. AJP’s employer, Oxford University has entered into a partnership with AstraZeneca for the development of a COVID-19 vaccine. AJP has received consulting fees for providing advice to Shionogi & Co., Ltd., on the development of the COVID-19 vaccine. AJP has received grants from Bill and Melinda Gates Foundation, Wellcome Trust, UK Research and Innovation Medical Research Council, and National Institute of Health and Care Research. YT, SO, RYS, KI, TH, MA, and TS are employees of Shionogi & Co., Ltd. TH and TS own stocks in Shionogi & Co., Ltd. YT owns stocks in Ono Pharmaceutical Co., Ltd. and Shionogi & Co., Ltd.
